非选择性β受体阻滞剂在肝硬化治疗中的应用

刘一锋; 王小泽; 杨丽

doi:10.3969/j.issn.1001-5256.2023.05.028

非选择性β受体阻滞剂在肝硬化治疗中的应用

DOI: 10.3969/j.issn.1001-5256.2023.05.028

刘一锋^{a, b},
王小泽^{a, b, , ,},
杨丽^{a, b}

a.
四川大学华西医院消化内科，成都 610041
b.
四川大学华西医院四川大学-牛津大学华西消化道肿瘤联合研究中心，成都 610041

基金项目:

四川省科技厅国际科技创新合作项目 (2021YFH0099)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王小泽负责拟定写作思路，资料分析，撰写论文；刘一锋参与检索文献，数据提取，修改论文；杨丽指导撰写文章并最后定稿。

详细信息

通信作者:
王小泽，wang_xiaoze@wchscu.cn (ORCID: 0000-0002-7169-9467)

计量
- 文章访问数: 396
- HTML全文浏览量: 124
- PDF下载量: 97
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-04
- 录用日期: 2022-12-05
- 出版日期: 2023-05-20

Advances in the application of nonselective β-receptor blockers in treatment of liver cirrhosis

Yifeng LIU^{a, b},
Xiaoze WANG^{a, b
, ,
,},
Li YANG^{a, b}

a.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China
b.
Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu 610041, China

Research funding:

International Cooperation Project of Sichuan Provincial Science and Technology Department （2021YFH0099）

More Information

Corresponding author: WANG Xiaoze, wang_xiaoze@wchscu.cn (ORCID: 0000-0002-7169-9467)

摘要

摘要: 非选择性β受体阻滞剂(NSBB)是肝硬化患者门静脉高压并发症防治的一线药物，广泛用于食管胃静脉曲张出血的一级预防和二级预防。近年来，在临床显著性门静脉高压(CSPH)患者中，NSBB已被证实还可以预防静脉曲张出血以外的其他肝硬化失代偿事件，如腹水和肝性脑病等。然而，在非CSPH的代偿期患者中，目前的研究证据不支持使用NSBB。尽管目前有可靠数据支持NSBB用于终末期肝硬化，但对于部分顽固性腹水和自发性腹膜炎患者仍存在用药安全问题，给药剂量和时机仍有待研究。本文综述了目前关于肝硬化患者使用NSBB(尤其是卡维地洛)的相关临床研究进展，并总结NSBB在肝硬化全程管理中合理应用的治疗窗口，为临床决策提供依据。
- 肝硬化 /
- 非选择性β受体阻滞剂 /
- 高血压, 门静脉 /
- 治疗学
Abstract: Nonselective β-receptor blockers (NSBBs) are first-line drugs for the prevention and treatment of complications in cirrhotic patients with portal hypertension and are widely used in the primary and secondary prevention of esophagogastric variceal bleeding. In recent years, studies have shown that in patients with clinically significant portal hypertension (CSPH), NSBBs can used to prevent liver decompensation events besides variceal bleeding, such as ascites and hepatic encephalopathy. However, in patients without CSPH, current research evidence does not support the use of NSBBs. Although reliable data currently support the use of NSBBs in end-stage liver cirrhosis, there are still drug safety issues in patients with refractory ascites and spontaneous bacterial peritonitis, and further studies are needed to explore the dose and timing of administration. This article reviews the clinical research advances in the use of NSBBs (especially carvedilol) in patients with liver cirrhosis and summarizes the therapeutic window used reasonably in the whole-course management of liver cirrhosis, so as to provide a basis for clinical decision-making.
- Liver Cirrhosis /
- Nonselective β-Blockers /
- Hypertension, Portal /
- Therapeutics

HTML全文

参考文献(41)

[1]	GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 221-234. DOI: 10.1038/s41575-018-0097-3.
[2]	LEBREC D, NOUEL O, CORBIC M, et al. Propranolol-a medical treatment for portal hypertension?[J]. Lancet, 1980, 2(8187): 180-182. DOI: 10.1016/s0140-6736(80)90063-x.
[3]	D'AMICO G, GARCIA-PAGAN JC, LUCA A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review[J]. Gastroenterology, 2006, 131(5): 1611-1624. DOI: 10.1053/j.gastro.2006.09.013.
[4]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
[5]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[6]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
[7]	SINAGRA E, PERRICONE G, D'AMICO M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(6): 557-568. DOI: 10.1111/apt.12634.
[8]	de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[9]	GLUUD LL, KRAG A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J]. Cochrane Database Syst Rev, 2012, 8(8): CD004544. DOI: 10.1002/14651858.CD004544.pub2.
[10]	ROCCARINA D, BEST LM, FREEMAN SC, et al. Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 4(4): CD013121. DOI: 10.1002/14651858.CD013121.pub2.
[11]	SHARMA M, SINGH S, DESAI V, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis[J]. Hepatology, 2019, 69(4): 1657-1675. DOI: 10.1002/hep.30220.
[12]	LO GH, CHEN WC, LIN CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding[J]. Hepatology, 2008, 48(2): 580-587. DOI: 10.1002/hep.22358.
[13]	SARIN SK, WADHAWAN M, AGARWAL SR, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding[J]. Am J Gastroenterol, 2005, 100(4): 797-804. DOI: 10.1111/j.1572-0241.2005.40468.x.
[14]	REIBERGER T, ULBRICH G, FERLITSCH A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11): 1634-1641. DOI: 10.1136/gutjnl-2012-304038.
[15]	SHAH HA, AZAM Z, RAUF J, et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial[J]. J Hepatol, 2014, 60(4): 757-764. DOI: 10.1016/j.jhep.2013.11.019.
[16]	TRIPATHI D, FERGUSON JW, KOCHAR N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J]. Hepatology, 2009, 50(3): 825-833. DOI: 10.1002/hep.23045.
[17]	MCDOWELL HR, CHUAH CS, TRIPATHI D, et al. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study[J]. Aliment Pharmacol Ther, 2021, 53(4): 531-539. DOI: 10.1111/apt.16189.
[18]	VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2019, 393(10181): 1597-1608. DOI: 10.1016/S0140-6736(18)31875-0.
[19]	RAFAILIDIS S, DEMERTZIDIS C, BALLAS K, et al. Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats[J]. World J Gastroenterol, 2009, 15(34): 4284-4289. DOI: 10.3748/wjg.15.4284.
[20]	GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254-2261. DOI: 10.1056/NEJMoa044456.
[21]	QI XS, BAO YX, BAI M, et al. Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis[J]. World J Gastroenterol, 2015, 21(10): 3100-3108. DOI: 10.3748/wjg.v21.i10.3100.
[22]	MERKEL C, MARIN R, ANGELI P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis[J]. Gastroenterology, 2004, 127(2): 476-484. DOI: 10.1053/j.gastro.2004.05.004.
[23]	BHARDWAJ A, KEDARISETTY CK, VASHISHTHA C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial[J]. Gut, 2017, 66(10): 1838-1843. DOI: 10.1136/gutjnl-2016-311735.
[24]	ALBILLOS A, ZAMORA J, MARTÍNEZ J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4): 1219-1231. DOI: 10.1002/hep.29267.
[25]	HOLSTER IL, TJWA ET, MOELKER A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding[J]. Hepatology, 2016, 63(2): 581-589. DOI: 10.1002/hep.28318.
[26]	SAUERBRUCH T, MENGEL M, DOLLINGER M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy[J]. Gastroenterology, 2015, 149(3): 660-668. DOI: 10.1053/j.gastro.2015.05.011.
[27]	LO GH, CHEN WC, WANG HM, et al. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding[J]. J Gastroenterol Hepatol, 2012, 27(11): 1681-1687. DOI: 10.1111/j.1440-1746.2012.07244.x.
[28]	STANLEY AJ, DICKSON S, HAYES PC, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding[J]. J Hepatol, 2014, 61(5): 1014-1019. DOI: 10.1016/j.jhep.2014.06.015.
[29]	YANG J, GE K, CHEN L, et al. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis[J]. Eur J Gastroenterol Hepatol, 2019, 31(12): 1518-1526. DOI: 10.1097/MEG.0000000000001442.
[30]	JACHS M, HARTL L, SIMBRUNNER B, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis[J]. Clin Gastroenterol Hepatol, 2022. DOI: 10.1016/j.cgh.2022.06.007.[Online ahead of print]
[31]	SERSTÉ T, MELOT C, FRANCOZ C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010, 52(3): 1017-1022. DOI: 10.1002/hep.23775.
[32]	BANG UC, BENFIELD T, HYLDSTRUP L, et al. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers[J]. Liver Int, 2016, 36(9): 1304-1312. DOI: 10.1111/liv.13119.
[33]	ROBINS A, BOWDEN A, WATSON W, et al. Beta-blockers in cirrhosis patients with refractory ascites[J]. Hepatology, 2014, 59(5): 2054-2055. DOI: 10.1002/hep.26676.
[34]	TERGAST TL, KIMMANN M, LASER H, et al. Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(6): 696-706. DOI: 10.1111/apt.15439.
[35]	BOSSEN L, KRAG A, VILSTRUP H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients[J]. Hepatology, 2016, 63(6): 1968-1976. DOI: 10.1002/hep.28352.
[36]	ADAY AW, MAYO MJ, ELLIOTT A, et al. The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites[J]. Am J Med Sci, 2016, 351(2): 169-176. DOI: 10.1016/j.amjms.2015.11.018.
[37]	WONG RJ, ROBINSON A, GINZBERG D, et al. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis[J]. Liver Int, 2019, 39(6): 1080-1088. DOI: 10.1111/liv.14040.
[38]	MANDORFER M, BOTA S, SCHWABL P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Gastroenterology, 2014, 146(7): 1680-1690. DOI: 10.1053/j.gastro.2014.03.005.
[39]	TREBICKA J, MACNAUGHTAN J, SCHNABL B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75(Suppl 1): S67-S81. DOI: 10.1016/j.jhep.2020.11.013.
[40]	VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology, 2016, 63(1): 197-206. DOI: 10.1002/hep.28264.
[41]	BLASCO-ALGORA S, MASEGOSA-ATAZ J, ALONSO S, et al. Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function[J]. BMJ Open Gastroenterol, 2016, 3(1): e000104. DOI: 10.1136/bmjgast-2016-000104.